Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? by De Ferrari, Laura et al.
Workflow: Annotated pdf, CrossRef and tracked changes
PROOF COVER SHEET
Journal acronym: IERX
Author(s): Laura De Ferrari, Alessandra Chiappori, Diego Bagnasco, Anna Maria Riccio,
Giovanni Passalacqua and Giorgio Walter Canonica
Article title: Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe
asthma?
Article no: 1111763
Enclosures: 1) Query sheet
2) Article proofs
Dear Author,
1. Please check these proofs carefully. It is the responsibility of the corresponding author to check these and approve or amend
them. A second proof is not normally provided. Taylor & Francis cannot be held responsible for uncorrected errors, even if
introduced during the production process. Once your corrections have been added to the article, it will be considered ready for
publication.
Please limit changes at this stage to the correction of errors. You should not make trivial changes, improve prose style, add new
material, or delete existing material at this stage. You may be charged if your corrections are excessive (we would not expect
corrections to exceed 30 changes).
For detailed guidance on how to check your proofs, please paste this address into a new browser window:
http://journalauthors.tandf.co.uk/production/checkingproofs.asp
Your PDF proof file has been enabled so that you can comment on the proof directly using Adobe Acrobat. If you wish to do this,
please save the file to your hard disk first. For further information on marking corrections using Acrobat, please paste this address
into a new browser window: http://journalauthors.tandf.co.uk/production/acrobat.asp
2. Please review the table of contributors below and confirm that the first and last names are structured correctly and that
the authors are listed in the correct order of contribution. This check is to ensure that your name will appear correctly online
and when the article is indexed.
Sequence Prefix Given name(s) Surname Suffix
1 Laura De Ferrari
2 Alessandra Chiappori
3 Diego Bagnasco
4 Anna Maria Riccio
5 Giovanni Passalacqua
6 Giorgio Walter Canonica
Queries are marked in the margins of the proofs, and you can also click the hyperlinks below.
Content changes made during copy-editing are shown as tracked changes. Inserted text is in red font and revisions have a red
indicator ©. Changes can also be viewed using the list comments function. To correct the proofs, you should insert or delete text
following the instructions below, but do not add comments to the existing tracked changes.
AUTHOR QUERIES
General points:
1. Permissions: You have warranted that you have secured the necessary written permission from the appropriate copyright
owner for the reproduction of any text, illustration, or other material in your article. Please see
http://journalauthors.tandf.co.uk/permissions/usingThirdPartyMaterial.asp.
2. Third-party content: If there is third-party content in your article, please check that the rightsholder details for re-use are
shown correctly.
3. Affiliation: The corresponding author is responsible for ensuring that address and email details are correct for all the co-
authors. Affiliations given in the article should be the affiliation at the time the research was conducted. Please see
http://journalauthors.tandf.co.uk/preparation/writing.asp.
4. Funding: Was your research for this article funded by a funding agency? If so, please insert ‘This work was supported by
<insert the name of the funding agency in full>’, followed by the grant number in square brackets ‘[grant number xxxx]’.
5. Supplemental data and underlying research materials: Do you wish to include the location of the underlying research
materials (e.g. data, samples or models) for your article? If so, please insert this sentence before the reference section: ‘The
underlying research materials for this article can be accessed at <full link> / description of location [author to complete]’.
If your article includes supplemental data, the link will also be provided in this paragraph. See
<http://journalauthors.tandf.co.uk/preparation/multimedia.asp> for further explanation of supplemental data and
underlying research materials.
6. The CrossRef database (www.crossref.org/) has been used to validate the references. Changes resulting from mismatches
are tracked in red font.
AQ1 Please check whether the institution name is is set correctly.
AQ2 Both quotes and italics have been used for quotations. Please confirm if any one form can be retained or whether both are
present in the original quotation.
AQ3 Please provide notes for all annotations.
AQ4 Please check whether the edit is correct in this reference.
AQ5 Please provide cited date for Ref. [1].
AQ6 Please provide missing volume number/page number for the “Cox et al., 2015” references list entry.
AQ7 Please provide missing year of publication for the “Mosmann et al., 0000” references list entry.
AQ8 Please provide missing volume number/page number for the “Raundhal et al., 2015” references list entry.
AQ9 Please provide missing Publisher location for the “, 2008” references list entry.
How to make corrections to your proofs using Adobe Acrobat/Reader
Taylor & Francis offers you a choice of options to help you make corrections to your proofs. Your PDF proof file has been enabled
so that you can mark up the proof directly using Adobe Acrobat/Reader. This is the simplest and best way for you to ensure that
your corrections will be incorporated. If you wish to do this, please follow these instructions:
1. Save the file to your hard disk.
2. Check which version of Adobe Acrobat/Reader you have on your computer. You can do this by clicking on the “Help” tab, and
then “About”.
If Adobe Reader is not installed, you can get the latest version free from http://get.adobe.com/reader/.
3. If you have Adobe Acrobat/Reader 10 or a later version, click on the “Comment” link at the right-hand side to view the
Comments pane.
4. You can then select any text and mark it up for deletion or replacement, or insert new text as needed. Please note that these will
clearly be displayed in the Comments pane and secondary annotation is not needed to draw attention to your corrections. If you
need to include new sections of text, it is also possible to add a comment to the proofs. To do this, use the Sticky Note tool in the
task bar. Please also see our FAQs here:
http://journalauthors.tandf.co.uk/production/index.asp.
5. Make sure that you save the file when you close the document before uploading it to CATS using the “Upload File” button on
the online correction form. If you have more than one file, please zip them together and then upload the zip file.




Please note that full user guides for earlier versions of these programs are available from the Adobe Help pages by clicking on the
link “Previous versions” under the “Help and tutorials” heading from the relevant link above. Commenting functionality is available
from Adobe Reader 8.0 onwards and from Adobe Acrobat 7.0 onwards.
Firefox users: Firefox’s inbuilt PDF Viewer is set to the default; please see the following for instructions on how to use this and




we on our way towards
targeted therapy for severe
5 asthma?










Respiratory Diseases and Allergy
Clinic, DIMI-Department Internal
Medicine, University of Genoa, IRCCS
AOUS. Martino-IST, Genoa, Italy
‡L.D.F. and A.C. contributed equally to
this work.
*Author for correspondence:
Tel.: +39 010 554 890
Fax: +390 105 556 307
canonica@unige.it
Although different phenotypes of severe asthma can be identified, all are characterized by
common symptoms. Due to their heterogeneity, they exhibit differences in pathogenesis,
etiology and clinical responses to therapeutic approaches. The identification of distinct mole-
10 cular phenotypes to define severe asthmatic patients will allow us to better understand the
pathophysiology of the disease and thus to more precisely target the treatment for each
patient. To achieve this goal, a systematic search for new, reliable and stable biomarkers
specific for each phenotype is essential. This review focuses on the current known molecular
phenotypes of severe asthma and highlights the need for biomarkers that could (either alone
15 or in combination) be predictive of the treatment outcome.
KEYWORDS: severe asthma ● molecular phenotypes ● biomarkers ● personalized medicine ● target therapy ●
monoclonal antibodies ● T helper 2
Bronchial asthma is a highly prevalent chronic
respiratory disease. It may be heterogeneous in
20  etiology, pathogenesis, clinical manifestations
and outcomes. Comorbidities, pathogenic
aspects, symptom severity, natural history,
treatment responsiveness and extrinsic and/or
intrinsic factors are primarily responsible  for
25 this variability. According to the Global
Initiative for Asthma Guidelines, asthma sever-
ity is classifiable based on different levels of
intensity, with an estimated 5 –10% of patients
suffering from severe asthma.[1] As recently
30 described by the American Thorax Society/
European Respiratory Society Taskforce, “severe
asthma requires treatment with high dose inhaled
corticosteroids plus a second controller (and/or
systemic corticosteroids) to prevent it from becom-
35 ing uncontrolled or which remains uncontrolled
despite this therapy.”[2] This context demon-
strates the true refractory nature of asthma.[3]
Despite the fact that pathogenic mechanisms
of severe asthma have been detailed over the
40years, only a single clinical approach remains
available for most patients. Over the last
AQ1
few
decades, technological advances have achieved
relevant progress, thereby providing significant
improvements in the understanding and man-
45agement of severe asthma.[4,5] Data from
genomics, proteomics, transcriptomics, meta-
bolomics and epigenetics studies demonstrated
distinct functional and pathological mechan-
isms related to specific biomarkers and differ-
50ent treatment responses for the severe asthma
phenotypes. This clinical entity was introduced
into clinical practice several years ago and
became increasingly known, accepted and
shared.[6] As mentioned above, key elements AQ2
55are needed to cluster and better characterize
patients to identify the phenotypes. Recently,
it has been established that a single clinical
characteristic is not adequate to define a phe-
notype if it is not integrated with several other
60factors. This integration of genetics, biology
and clinical aspects should lead to better
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identified phenotypes matched to biomarkers and provide prog-
nostic and potential therapeutic information, thereby resulting
in an improved understanding of asthma pathogenesis and an
65 increased ability to effectively treat complex heterogeneous dis-
eases such as severe asthma. A successful identification of reliable
and specific biomarkers for severe asthma should be the basis for
the introduction of biomarker-related personalized medicine,
where clinicians could be oriented to a specific therapeutic
70 approach and severe asthmatics could receive the most effective
drug or biological agent on the basis of their single profile.[7–9]
In this review,  the authors will focus on severe asthma and
provide an overview of the evolving biomarkers, molecular
phenotypes and target-related therapies, paying special attention
75 to lymphocyte Th 2 and non-Th2 pathways.
 Biomarkers of severe asthma: an overview
In clinical practice, an ideal biomarker is a physical trait or a
laboratory measurement that is reliable and reproducible and can
help identify the best therapeutic approach, track changes in
80 disease activity, confirm a diagnosis or predict a response. It
should also be easy to collect and evaluate, non invasive and
inexpensive.[10,11] For example, in asthma and airway disease
management, biomarkers can be assessed in the sputum,[12–15]
bronchoalveolar lavage fluid (BALF),[16,17] bronchial epithelial
85 brushings,[16,18] bronchial biopsies,[19,20] exhaled air via frac-
tional exhaled nitric oxide (FeNO) evaluation,[13,21–24] exhaled
breath condensate (EBC) analysis,[25–28] peripheral blood
[12,13,29] and urine.[30,31] Diagnostic procedures such as
bronchoalveolar lavage, bronchoscopy or bronchial biopsy are
90 sometimes additionally used to evaluate airway inflammation
and remodel ing and to provide detailed pathological information
on the patient’s condition. Nonetheless, these are invasive tech-
niques that may be risky and are not easily applicable in severe
asthma patients. Compared to bronchoalveolar lavage and endo-
95 scopy with bronchial specimen collection, spontaneous or
induced sputum cell counts have been the method of choice to
investigate the inflammatory pattern of bronchial tissues for a
long time.[32] Subjects with a concurrent increase in eosinophils
(≥2%) and neutrophils (≥40%) usually have the clinical charac-
100 teristics of severe asthma.[33] Several studies have demonstrated
the high reproducibility of sputum eosinophil and neutrophil
counts and proposed them as an index for the therapeutic adjust-
ment and prediction of exacerbation or steroid responsiveness.
[34,35] Blood eosinophilia was recently confirmed to be the best
105 surrogate marker for the identification of sputum eosinophilia in
moderate -to -severe asthma patients; this analysis was more speci-
fic and accurate then FeNO levels and serum periostin.[13] Over
time, sputum and the other above-mentioned samples have
become substrates for the implementation of new clinical research
110 techniques and trials. The aim of previous studies was essentially
to investigate cytokines (primarily Th1/Th2), chemokines,
growth factors, metabolites, proteins and gene expression with a
recognized or hypothetical pathogenic role in severe asthma. To
date, the most relevant cells and mediators considered to be
115 promising biomarkers are those belonging to the type 2 immune
response pathway; these biomarkers are known to be inherent to
severe allergic asthma, which is the most common form of severe
asthma.[2] The existence of two different functional subsets of
human CD4+ T cells (termed T h1 and T h2) that produce
120distinct cytokine panels was demonstrated in mice in 1986 by
Mossman et al. and later in human T cells.[36,37] During allergic
sensitization and the immune response to allergic stimuli, the
respiratory epithelium produces cytokines and chemokines such
as thymic stromal lymphopoietin , IL -25 and IL-33. These mole-
125cules enhance the Th2 immune response by activating pulmonary
dendritic cells and inducing the maturation of CD4+ progenitor
cells towards a CD4+  Th2 functional cellular profile.[38]
Activated Th2 cells produce specific cytokines (i.e., IL-4, IL-5,
IL-9 and IL-13) that favo r and enhance the Th2 response. IL-5 is
130the primary specific trigger for eosinophils. It drives the hemato-
poietic process from their bone marrow progenitors (CD34+IL-
5Rα+) to their release, activation and tissue recruitment.[39] IL-
9, which was previously classified as an exclusive Th2 cytokine, is
also secreted by another novel subtype of CD4 + T cells termed
135Th9 cells. IL-9 induces T cell activation and mast cell prolifera-
tion and differentiation.[40] IL-4 and IL-13 are crucial for type 2
inflammation. These cytokines share a common receptor sub-
chain (IL-4Rα) that is present in both type 1 (IL-4 exclusive) and
type 2 (IL-4 and IL-13) receptors. IL-4 and IL-13 synergistically
140promote the allergen-specific synthesis of immunoglobulin E
(IgE) from B lymphocytes. The secreted IgE binds to its receptor
FcεRI on mast cells and basophils, resulting in its opsonization.
Allergen-IgE complexes trigger the release of a cascade of pre-
formed pro-inflammatory mediators (cytokines, interleukins,
145prostaglandins and leukotrienes) that contribute to inflammatory
cell recruitment.[41] Moreover, IL-4/IL-13 together play a key
role in airway remode ling and inflammation, causing increased
 NO production, airway hyperresponsiveness, goblet cell hyper-
plasia, mucus hypersecretion, the induction of epithelial inducible
150nitric oxide synthase  (only IL-13) and periostin expression in
bronchial epithelial cells and lung fibroblasts.[42] The measure-
ment of FeNO is a simple, quantitative, non invasive, reproduci-
ble and safe method to assess airway Th2 and eosinophilic
inflammation and to monitor the responsiveness of inhaled corti-
155costeroid (ICS) therapy.[22,43] It has been standardized for
clinical use in adults and children but is not considered to be
an effective biomarker for severe asthma management.[2]
Periostin is a secreted matricellular protein that is involved in
chronic inflammation in allergic diseases and tissue remodel ing.
160[44,45] Thus, serum periostin is considered to be a promising
marker of Th2 inflammation and airway eosinophilia despite
the fact that it is not lung  specific.[12,18,46] We recently
studied airway remodel ing in severe allergic asthma patients
treated with omalizumab. We evaluated bronchial biopsies col-
165lected pre treatment and 12 months after anti-IgE therapy using
morphometric and proteomic approaches.[19,20] The authors’
data showed that Galectin-3 could serve as a predictive biomar-
ker of airway remode ling improvement.
Th2 cytokines also trigger the production of eotaxins, which
170are strong chemoattractant proteins. Eotaxin-1 is involved in
2 Expert Rev. Respir. Med. 00(00), (2015)
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eosinophil recruitment and activation and has been detected in
the blood, sputum, BALF and EBC. Recently, Wu et al. pro-
posed eotaxin-1 as a novel potential biomarker for the assess-
ment of asthma severity and control status.[47]
175 Finally, various markers of airway nitrosative/oxidative stress
and inflammation (leukotrienes and lipoxines) have been found
to be elevated in EBC from severe asthmatics compared with
healthy subjects.[27,48]
Leukotrienes are released from various cells, including eosi-
180 nophils, neutrophils and mast cells, and can also be detected in
the urine. Urinary leukotriene E4 is used as a systemic marker of
LT production, and high levels in asthmatic patients seem to be
linked to a better response to leukotriene antagonist adminis-
tration [30] (Figure 1).
185 Despite on going treatment with high doses of ICS, some
severe asthmatics present a Th1 inflammatory signature char-
acterized by the production of IFN)-γ and reduced Th2 and IL-
17 responses.[49] However, Th17 cells (CD4+IL-17+ expres-
sing T cells) have been recognized to play a key role in the
190 promotion of neutrophil selective migration to the site of airway
inflammation.[50]
 Severe asthma molecular phenotyping
As mentioned above, severe asthma patients are heterogeneous in
terms of their severity, natural history and treatment responsive-
195 ness; this heterogeneity is partially related to the underlying
mechanisms. Nonetheless, they are characterized by common
features that allow clinicians to group them into so-called
“phenotypes.” [6] In this context, phenotype means “the obser-
vable properties of an organism that are produced by the interaction
200 of the genotype and the environment.” [51] Each phenotype exhi-
bits a subtype of a condition that is defined by distinct functional
or pathophysiological mechanisms. These features or pathways
are defined as “endotypes.” [6,52] By applying the clinically
oriented phenotype definition to traditional medicine, we can
205say that a “phenotype” is the result of a specific interaction
between a patient’s genes and the environment, and many differ-
ent approaches have been proposed to characterize these sub-
groups in severe asthma. Clinical, biological and physiological
characteristics have been used to classify the different forms of
210asthma.[53] Severe asthma phenotypes are currently identifiable
by two main strategies: a hypothesis-based approach and an
unbiased approach. Severe asthma phenotyping began decades
ago using a biased approach. Patients were classified into broad
categories based upon a single variable, including disease severity,
215symptomatic triggers, age at onset, patterns of inflammation,
exacerbations and airflow obstruction.[54–56] Using this
approach, overlaps between different groups were common. In
contrast, the statistically unbiased approach attempted to cluster
patients to avoid the clinical biases. The Severe Asthma Research
220Program (SARP) study identified five asthma clusters using an
unsupervised hierarchical analysis of the predominant clinical
features. Each of the clusters contained subjects who met the
ATS definition of severe asthma.[57] Another SARP study was
performed on 161 asthmatic children. The authors identified
225four phenotypic clusters and placed children with severe asthma
into each cluster.[58] Recently, Schatz et al. performed a post hoc
cluster analysis on a large number of severe or difficult-to-treat
asthmatic children, adolescents and adults belonging to “The
Epidemiology and Natural History of Asthma: Outcomes and
230Treatment Regimens”  study cohort. Cluster-defining variables
were chosen, including sex, race, atopy, age at onset and others.
Five clusters were identified in each age stratum, and the associa-


















































Figure 1. Biomarker discovery and phenotyping in severe asthma: actuality and perspectives. FeNO: Fractional exhaled nitric
oxide; FRC: Functional residual capacity; Gal-3: Galectin-3; IgE: Immunoglobulin E; RV: Residual volume; uLTE4: Urinary
leukotriene E4. 
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searched. The results confirmed the existence of distinct pheno-
235 types that were related to outcomes in adults and adolescents but
not in children.[59] It became progressively clear that the above-
mentioned clinical clusters were not adequate to fully explain and
clarify patients’ phenotypes. Thus, studies of molecular pheno-
typing analysis were developed to investigate the molecular path-
240 ways underlying the clinical phenotypes. In a randomized control
trial, Woodruff et al. analyz ed airway epithelial brushings from 42
mild-to-moderate non smoking asthmatic patients and non smok-
ing healthy subjects using microarray and PCR analyz es. The
authors also investigated airway epithelium gene expression to
245 explore its possible dysfunctional mechanism in asthma and
reported that the chloride channel, calcium-activated, family mem-
ber 1 (CLCA1), periostin, and serine peptidase inhibitor, clade B
(ovalbumin), and member 2 (serpinB2) genes were up regulated in
the asthma patients. In in vitro studies, the authors found that
250 this enhanced gene expression was stimulated by IL-13.[60]
Based on the hypothesis that IL-13 could be used to identify
subsets of asthma patients, the gene expression of cells isolated
from epithelial brushing were re-evaluated by taking the high or
low expression of IL-13-inducible genes into consideration. The
255 experimental results suggested the classification of asthmatic
patients into cohorts in two subgroups according to the degree
of Th2-driven inflammation. IL-5 and IL-13 expression, airway
hyperresponsiveness, ICS responsiveness, serum IgE and blood
and airway eosinophilia were significantly increased in the “Th2-
260 high” group versus the “Th2-low” group/healthy controls.[18]
The authors analyz ed induced sputum cells from 37 asthmatic
patients and 15 healthy control subjects to better profile the
epithelial cell gene expression following IL-13 exposure. The
genes evaluated included periostin, LCA1 and SERPINB2, Th2
265 genes and other genes involved in the T h2 response. Periostin
and CLCA1 (but not SerpinB2) exhibited significantly increased
expression in the sputum-obtained cells from asthmatic subjects.
Induced sputum proved to be an easy-to-collect biological sample
method for molecular evaluation. IL-4, IL-5 and IL-13 tran-
270 scripts could be easily detected in sputum cells from asthmatic
patients, and their expression levels were proposed for use to
classify asthma into Th2-high and Th2-low endotypes.[14]
Thus, the concept of “severe asthma molecular phenotypes” was
defined.
275  Th2-high phenotypes, their biomarkers and targeted
therapy
Historically, asthma has been always considered a Th2 disease
that is linked to atopy, allergy and eosinophilic inflammation,
and therefore, is responsive to corticosteroids (CSs). The major-
280 ity of patients fit this common context, but asthmatics are a
heterogeneous group that range from allergic asthma to aspirin-
induced asthma to exercise-induced asthma (EIA) [61]
(Figure 2).  EIA is usually found in individuals who suffer
from bronchoconstriction following strenuous exercise, fre-
285 quently under cold and dry conditions. In this phenotype,
increased levels of mast cells and their mediators can be observed
in addition to the Th2 component, although the underlying
inflammatory response is not fully understood and no specific
biomarker has been described.[62] These subjects are often
290responsive to anti-IL-9 therapy and cysteinyl leukotriene modi-
fiers, but they usually have milder asthma and therefore will not
be considered in this review.[63]
Overall, as the complexity of the immuno-inflammatory
background increases, additional immune pathways are likely
295to be engaged beyond the original Th2 core, leading to greater
severity and the reduction of  CS responsiveness.[64] Some
biomarkers have been associated with Th2 inflammation, but
many of them still need to be understood. Moreover, targeted
Th2 pathway inhibition in non-phenotyped patients is less
300frequently effective, and therefore, new biomarkers need to be
found to offer a tailored therapy to the patient (Figure 3).
 Early-onset allergic asthma
This group accounts for approximately 40–50% of all severe
asthmatics and includes subjects who developed their disease
305during childhood (often school age). These patients are char-
acterized by an atopic condition and Th2 inflammation. Early-
onset allergic asthma can present with mild -to -severe forms, and
it is not clear whether severe asthma is the result of a progression
from a milder form or instead arises as severe during childhood.
310[58] These patients are polysensitized, have high total IgE levels,
a frequent family history of atopy and a clearly identified
symptom exposure. Genome-wide association studies have evi-
denced a genetic component linked to early-onset asthma, and
the genes associated with this phenotype are epithelial-related
315rather than allergy-related.[65] Generally, CS therapy can mod-
ulate Th2 cytokines and associated inflammation, but its activity
is non specific. Thus, treatment with molecules that selectively
target components of the Th2 pathway will be more appropri-
ate.[56] High FeNO levels, sputum eosinophils and increased
320airway periostin have been proposed as biomarkers for Th2-
associated asthma and could be used to identify patients respon-




















Figure 2. The primary defined Th2-high and Th2-low severe
asthma phenotypes. ICS: Inhaled corticosteroid.
4 Expert Rev. Respir. Med. 00(00), (2015)
Review De Ferrari et al.
subgroup of moderate -to -severe asthmatics with lung eosinophi-
lia who respond to therapy with a monoclonal antibody directed
325 against IL-13 (lebrikizumab), whereas IgE levels, atopy and
blood eosinophils do not allow the prediction of a favo rable
clinical response. Only subjects with a high serum concentration
of periostin showed an improvement in lung function para-
meters, and to a lesser extent exacerbations, following lebrikizu-
330 mab therapy.[66] Piper et al. recently evaluated another anti-IL-
13 antibody (tralokinumab). In this study, only patients with
sputum IL-13 levels above 10 ng/ml showed a good response,
with a significant improvement in the asthma control question-
naire score and forced expiratory volume in 1 s .[67] The pre-
335 sence of high IgE levels makes this group an ideal target for anti-
IgE treatment; however, the available data evidenced a modest
efficacy of omalizumab in severe asthma patients with high IgE.
[68,69] Recently, Hanania et al. described a retrospective ana-
lysis of a trial with omalizumab using the Th2 biomarkers
340 periostin, FeNO and blood eosinophils. The authors split the
asthmatics into two groups: subjects with high and low biomar-
ker values. Subjects with high levels of these biomarkers
responded better to omalizumab therapy than subjects with
lower levels. Moreover, patients on placebo therapy in the
345 Th2-high group had more frequent exacerbations than patients
without Th2-high-related inflammation.[22] Recently,  the
authors’ group demonstrated that the expression of Galectin-3
in bronchial biopsies of allergic severe asthma patients could also
be used to predict the modulation of airway remodel ing follow-
350 ing omalizumab treatment.[20] In a 12-week study, Corren
et al. failed to demonstrate significant efficacy of an antibody
to IL-4Rα in severe asthma patients, although a modest benefit
was seen in the most symptomatic subjects.[70] Recently, the
analysis of IL-4Rα polymorphisms allowed the identification of
355participants with a more favo rable IL-4Rα antagonist therapy
response.[71,72] A monoclonal antibody to IL-5 reduced blood
eosinophils but did not show significant efficacy in these
patients, suggesting that other inflammatory components may
have a more important role than eosinophils. Additional data
360would certainly improve our knowledge concerning the patho-
logical mechanisms involved in this phenotype and enhance our
tools for the prediction of the degree of the treatment response.
 Late-onset highly eosinophilic asthma
Several studies with patients characterized by late -onset dis-
365ease have observed persistent blood and lung eosinophilia
despite treatment with inhaled and oral CSs . This phenotype
represents a more heterogeneous and less well-defined group
of subjects and includes approximately 25% of severe asthma
patients.[56] Adult eosinophilic asthma is severe at the time
370of onset and is sometimes associated with chronic sinusitis
and nasal polyps without a clear atopy history. Moreover, this
group also includes patients with aspirin-exacerbated respira-
tory disease (AERD). AERD refers to patients with non-IgE-
mediated responses to aspirin and other cyclooxygenase-1
375inhibitors; the cysteinyl leukotriene pathway in these patients
is upregulated by Th2 cytokines. Eosinophilia is not specific
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Figure 3. Currently known aspects of asthma phenotypes. CXCR2: CXC chemokine receptor 2; FeNO: Fractional exhaled nitric
oxide; Ig: Immunoglobulin; IL4Rα: Interleukin 4 receptor alpha; LT: Leukotriene.
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more relevant. Many patients are characterized by a strong
Th2 skew, with increased FeNO, periostin, eotaxins, 15-
380 lipoxygenase-1 and 15-hydroxyeicosaetetranoic acid.[16,73]
Moreover, an increase in urinary cysteinyleukotrienes can be
observed. Generally, eosinophils undergo apoptosis in the
presence of CSs because Th2 inflammation is usually CS -
sensitive.[74] In this phenotype, a persistent eosinophilia is
385 indicative of CS refractoriness, and high systemic doses are
able to overcome this CS inefficacy.[75] The lack of a sig-
nificant response to CS treatment in this phenotype implies
that the Th2 process differs from the process associated with
the early-onset phenotype and is probably more complex.
390 However, late -onset persistent eosinophilic asthma is asso-
ciated with a better response to Th2-targeted therapy than
early -onset allergic asthma, and the presence of eosinophilic
inflammation detected in blood (or preferably sputum) iden-
tifies patients responsive to selective anti-eosinophilic thera-
395 pies, including anti-IL-5.[76] IL-5 is a quite selective
cytokine that is involved in the recruitment, maturation and
activation of eosinophils, and therefore, is an optimal target
for treatment. In these patients, the monoclonal antibody to
IL-5 (mepolizumab) decreased the exacerbation rate, allowed
400 systemic CS withdrawal and improved lung function.[77,78]
Another anti-IL-5 monoclonal antibody (reslizumab)
improved airway function compared  with the placebo.[79]
Moreover, beneficial effects on lung function in these indivi-
duals could also be obtained with 5-lipoxygenase inhibitors
405 and leukotriene modifiers.[80] Finally, Wenzel et al. found
that the IL-4Rα blocker pitrakinra was significantly better at
reducing the exacerbation rate compared with the placebo in
asthma patients with baseline blood eosinophils >350 mm 
3.
[81] Pitrakinra is a recombinant protein with a double inhi-
410 bitory effect on IL-4 and IL-13. It acts as a competitive
antagonist to prevent cell activation by binding to the α
subunit of the IL-4 receptor, which is shared by both cyto-
kines. Moreover, dupilumab (a human monoclonal antibody
to IL-4Rα) seems to be associated with fewer asthma exacer-
415 bations and improved lung function in moderate-to-severe
asthma patients with elevated eosinophil levels.[82]
 Th2-low phenotypes, their biomarkers and targeted
therapy
Th2-low asthma is generally identified by the absence of a clear
420 Th2 aspect because several other factors (i.e., Th1 and Th17
immunity, neutrophil inflammation, mast cell activation,
smooth muscle hyperreactivity, infection and oxidative stress)
seem to play more important roles. Th2-low asthma probably
represents a relevant percentage of all severe asthmatic patients,
425 and the lack of efficacy of Th2-targeted treatments, including
CSs , supports the existence of asthma phenotypes not character-
ized by Th2 immunity. However, because the phenotypes
included in this group are not well defined, detailed studies
are needed to enable the definition of new phenotypes, specific
430 biomarkers and clinical/pathological features.[83,84]
 Obesity-related asthma
These patients are most commonly women with severe symp-
toms despite a moderately preserved lung function. The patients
typically have a high body mass index, onset of disease in the
435fifth decade or later and less frequent history of allergic diseases.
[85] The obesity condition is associated with a generalized
inflammatory state with increased  TNF-α , IL-6 and leptin
expression, but confirmatory data are needed to identify poten-
tially useful specific biomarkers.[86] Murine models of obesity
440demonstrated that adiponectin played a protective role and was
inversely correlated with lung inflammation; however, in
humans these data are discordant.[87–89] Obesity-associated
asthma is usually less responsive to inhaled CS therapy than
allergic asthma.[18] Whether the lack of response to CSs is due
445to additional immune pathways is not fully understood. Dixon
et al. observed improvements in symptoms, quality of life and
bronchial hyperresponsiveness in a group of non allergic, obese,
late-onset subjects after weight loss was achieved following
bariatric surgery [90]; the same result was reported by
450Lombardi et al.[91]
 Neutrophilic asthma
Several authors have detected increased neutrophil counts in the
sputum, BALF and biopsy tissues from adult-onset, severely
obstructed patients that were associated with a high dose of CS
455therapy and sometimes with high past/current tobacco use.
Neutrophilia can co exist with eosinophilia. However, the defini-
tion of the specific role of neutrophils in asthma pathogenesis is
difficult because neutrophilic inflammation can also be the result
of concomitant diseases or can be derived from the CS inhibitory
460effect on the apoptosis of these cells.[92] Gene expression analysis
of cells from sputum found increased expression of the TNF-α
pathway and IL-1 concentrations in patients with neutrophilic
asthma, although anti-TNF-α therapy did not show significant
clinical efficacy in these subjects.[93,94] Enhanced expression of
465α-defensins and neutrophil proteases was also detected in the
peripheral blood of these patients.[95] Moreover, the presence
of neutrophils was associated with increased levels of matrix
metalloproteinase 9 in the BALF and tissues, and these high
concentrations were not reduced by CS treatment. Whether
470Th17 lymphocytes are involved in the pathological process is
not clear because the majority of the data are derived from
experimental models and studies in humans have not associated
Th17 pathways with neutrophil asthma inflammation.[96]
Currently, there are few neutrophil asthma-targeting drugs.
475Macrolide antibiotics have an anti-neutrophilic activity, and
recently a CXC chemokine receptor 2 antagonist was shown to
decrease sputum neutrophils in severe asthmatics.[97,98]
 Other possible phenotypes
It is very likely that new distinct phenotypes will be added in the
480future to those described here based on current knowledge.[99]
Further studies are necessary to better characterize severe asthma
patients. Many authors have agreed with the existence of a pauci-
granulocytic phenotype characterized by the absence of an
6 Expert Rev. Respir. Med. 00(00), (2015)
Review De Ferrari et al.
observable inflammatory process and a general lack of both sputum
485 eosinophils and neutrophils. In this case, the underlying pathological
mechanisms are poorly understood and add further difficulty to the
selection of appropriate therapeutic approaches. Furthermore, smok-
ing-associated asthma may also be a distinct phenotype that overlaps
with chronic obstructive pulmonary disease.[100]
490 Conclusions
The so-called “personalized medicine” is expected to be more
advantageous and possibly more cost-effective than the current
diagnostic and clinical approach. A number of important aspects
are still under investigation, including the identification of biomar-
495 kers that can be used to predict patient progression and therapeutic
responses.[101,102] A more detailed investigation into biomarkers
may help clinicians determine the best treatment based on the
phenotype and the expected response. “Omics” approaches (geno-
mics, proteomics and metabolomics) are expected to be of great
500 help in identifying biomarkers and phenotypes. Currently, several
drugs acting at different levels in the cascade of reactions involved
in Th2 pathogenesis are under investigation, whereas there has
been less progress for the so-called non-Th2 asthma (the obesity-
related, neutrophilic and paucigranulocytic phenotypes).[103]
505 The identification of new asthma phenotypes is essential to make
the best use of the newmonoclonal drugs still under study and in the
experimental phases. The possibility of introducing these biologicals
in therapy allows us to integrate high -dosage therapy that often fails
to control the symptoms of patients with severe asthma. The coop-
510 eration between academia, research and the pharmaceutical industry
could provide new resources and tools to seek new phenotypes of
severe asthma and related biomarkers for characterization.[104]
Expert commentary
The advances in the field of biomedical research are changing the
515 world and contributing to the expansion and improvement of our
knowledge, with important, crucial consequences for the manage-
ment of complex and difficult to treat diseases such as severe
asthma. Along the pathway of hard sciences, we progressively
abandoned traditional reactive medicine, mass targeted therapy
520and descriptive studies. According to the concept of “heterogeneity
of severe asthma,” we focused our resources on phenotyping and
investigating molecular pathways that led to more stratified med-
icine. Many biological drugs for Th2 pathway targets and specific
biomarkers for severe asthma phenotypes and endotypes are now
525available in clinical practice. However, the state of the art in
biomarker discovery and phenotyping still does not allow us to
plan a personalized therapeutic approach and to predict the patho-
logical evolution of severe asthma patients.
Five-year view
530The recent advances in immunology, genetics and “omics” sciences
have allowed us to better understand complex diseases such as
severe asthma, which still represents a diagnostic and therapeutic
challenge for clinicians. Research has focused on an improved and
refined definition of the phenotypes and the identification of
535biomarkers that will allow a more accurate diagnosis and targeted
prescription. According to recent opinions, it is important to move
from generalized and standardiz ed medicine, where every severe
asthma patient is treated only on the basis of his/her symptoms, to
personalized medicine where each subject will receive the best
540targeted therapy.[105] Severe asthma patients should be referred
to highly specialized Asthma Units whenever possible to optimize
both patient outcomes and the cost-effectiveness of the new bio-
logical agents and to improve our current knowledge of asthma
mechanisms. This integrated approach by experienced clinicians
545and researchers would surely help to identify the definitive pathway
to personalized medicine for asthma.
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Key issues
● The heterogeneity of severe asthma limits its characterization and makes the selection of appropriate therapeutic approaches difficult.
● The response to an anti-inflammatory drug depends on the presence of a specific type of airway inflammation.
● A biomarker can be indicative of a specific inflammatory process.
● A biomarker can be useful for the prediction of the degree of treatment response.
● New biomarkers need to be identified to allow clinicians to choose the most appropriate targeted therapy for each patient.
● In many cases, the characterization of patients with severe asthma with a single biomarker is not sufficient to identify the specific
phenotype.
● Understanding the immune pathways beyond severe asthma inflammation is moving the concept of clinical phenotypes towards the
concept of molecular phenotypes.
● Panels of different, non invasive, stable biomarkers should be studied for application in daily clinical practice.
● Severe asthma patients should be referred to specialized units for optimal disease management.
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